Jinwon Life Sciences Registers 50% of Subjects for Phase 2 Clinical Trial of COVID-19 'Nasal Spray Treatment'
Additional Secondary Clinical Trial Centers in High-Infection Areas
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 7th that the enrollment of clinical trial subjects for the Phase 2 clinical study of GLS-1200, a nasal spray treatment for preventing novel coronavirus infection (COVID-19) approved by the U.S. Food and Drug Administration (FDA), has reached 50%, and that a second clinical trial center has been added in Baton Rouge, Louisiana, the epicenter of the COVID-19 outbreak in the U.S. with numerous infection cases, in collaboration with the Clinical Research Center at the University of Pennsylvania.
The company explained that the Phase 2 clinical study of GLS-1200 is accelerating, and that adding high-infection areas to the clinical research increases the opportunity to verify the efficacy of GLS-1200.
Furthermore, GLS-1200 has exclusively secured the global development rights for the product and related technologies from a specialized research group at the University of Pennsylvania in the U.S., and has filed patents for treatment of bacterial infections such as sinusitis, as well as for inhibition of COVID-19 and other viral infections.
Park Younggeun, CEO of GeneOne Life Science, stated, “Our company has been leading the development of products responding to the COVID-19 infectious disease,” and added, “We expect GLS-1200 to play an effective role in suppressing the spread of COVID-19.”
He also emphasized, “The ingredients of GLS-1200 are natural substances that have been used in the human body for hundreds of years, not synthetic compounds, and after the COVID-19 pandemic, we plan to expand its application to upper respiratory viral infections such as influenza.”
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Report] "I Think Twice Before Going to a Store"... Starbucks '5/18 Tank Day' Controversy Grows
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A company official also stated, “Our company is currently developing GLS-5310, a COVID-19 vaccine that addresses virus variants, applies a low-cost and convenient administration method, and enables mass production and supply of vaccines. Additionally, we are preparing for Phase 2 clinical trials in the U.S. of GLS-1027, an oral COVID-19 treatment drug that suppresses cytokine storms caused by COVID-19 infection.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
